Bayesian Capital Management LP bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,029 shares of the company’s stock, valued at approximately $267,000.
A number of other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in Keros Therapeutics by 356.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock worth $138,000 after acquiring an additional 2,702 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares in the last quarter. Arizona State Retirement System acquired a new position in Keros Therapeutics during the fourth quarter worth $231,000. CANADA LIFE ASSURANCE Co raised its stake in Keros Therapeutics by 117.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock worth $345,000 after acquiring an additional 2,822 shares in the last quarter. Finally, Perpetual Ltd acquired a new position in Keros Therapeutics during the first quarter worth $443,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
KROS has been the subject of several recent analyst reports. Truist Financial reiterated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Oppenheimer began coverage on Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $92.17.
Keros Therapeutics Stock Performance
Shares of KROS stock opened at $50.16 on Thursday. The stock’s fifty day moving average is $47.34 and its 200-day moving average is $55.41. The stock has a market capitalization of $1.81 billion, a PE ratio of -9.74 and a beta of 1.23. Keros Therapeutics, Inc. has a 52 week low of $27.02 and a 52 week high of $73.00.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.12. The firm had revenue of $0.08 million during the quarter. The firm’s revenue was down 97.3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.26) EPS. As a group, analysts forecast that Keros Therapeutics, Inc. will post -4.8 earnings per share for the current fiscal year.
Keros Therapeutics Profile
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Articles
- Five stocks we like better than Keros Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- Russell 2000 Index Bull Run: This ETF is Poised for Growth
- Best Aerospace Stocks Investing
- Time To Pick Up the Pieces of Starbucks’ Broken Growth Story
- Best Stocks Under $5.00
- 3 AI Stocks That You Can Buy and Hold Forever
Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report).
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.